Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CRSP

CRISPR Therapeutics AG

Dec 08 • 04:00PM ET

64.54

Dollar change -5.67
Percentage change -8.08	%

Healthcare • Biotechnology • Switzerland • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.48	Insider Own	3.98%	Shs Outstand	78.51M	Perf Week	-5.99%
Market Cap	5.13B	Forward P/E	-	EPS next Y	-6.58	Insider Trans	0.00%	Shs Float	76.27M	Perf Month	17.95%
Income	-353.53M	PEG	-	EPS next Q	-0.99	Inst Own	63.48%	Short Float / Ratio	21.46% / 8.37	Perf Quarter	29.24%
Sales	170.01M	P/S	30.15	EPS this Y	58.50%	Inst Trans	-0.05%	Short Interest	16.37M	Perf Half Y	3.12%
Book/sh	21.75	P/B	2.97	EPS next Y	-89.66%	ROA	-15.92%	Target Price	89.64	Perf Year	27.10%
Cash/sh	21.90	P/C	2.95	EPS next 5Y	-	ROE	-19.20%	52W Range	37.55 - 76.19	Perf YTD	58.77%
Dividend	-	P/FCF	-	EPS past 5Y	-37.42%	ROI	-18.09%	52W High	-15.29%	Beta	1.75
Dividend %	-	Quick Ratio	15.83	Sales past 5Y	27206.56%	Gross Margin	32.69%	52W Low	71.88%	ATR	4.97
Employees	458	Current Ratio	15.83	Sales Q/Q	-100.00%	Oper. Margin	-235.43%	RSI (14)	53.00	Volatility	9.38% 7.91%
Optionable	Yes	Debt/Eq	0.14	EPS Q/Q	36.88%	Profit Margin	-207.95%	Rel Volume	8.77	Prev Close	70.21
Shortable	Yes	LT Debt/Eq	0.13	Earnings	Nov 06 AMC	Payout	-	Avg Volume	1.96M	Price	64.54
Recom	2.07	SMA20	-1.12%	SMA50	22.89%	SMA200	22.26%	Volume	17,171,663	Change	-8.08%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-27-23	Initiated	Mizuho	Buy	$82
Aug-17-23	Upgrade	Citigroup	Neutral → Buy
May-30-23	Initiated	William Blair	Outperform	$75
Apr-13-23	Initiated	Cantor Fitzgerald	Overweight	$72
Mar-21-23	Initiated	Bernstein	Mkt Perform	$44
Mar-17-23	Initiated	Bryan Garnier	Buy	$70
Mar-07-23	Initiated	Robert W. Baird	Neutral	$46
Oct-11-22	Initiated	Morgan Stanley	Underweight	$37
Aug-09-22	Downgrade	Barclays	Overweight → Equal Weight	$99 → $88
Jun-23-22	Downgrade	Evercore ISI	Outperform → In-line	$66 → $60
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$98
Apr-28-22	Initiated	Credit Suisse	Neutral	$78
Dec-07-21	Initiated	Cowen	Market Perform
Oct-19-21	Initiated	SVB Leerink	Outperform	$126
Jun-14-21	Upgrade	Citigroup	Sell → Neutral	$55 → $132
Apr-21-21	Upgrade	Jefferies	Hold → Buy	$172
Mar-04-21	Initiated	JMP Securities	Mkt Outperform	$160
Dec-10-20	Reiterated	Needham	Buy	$105 → $170
Dec-10-20	Reiterated	Chardan Capital Markets	Buy	$110 → $166

Show Previous Ratings

Today 05:00PM	Vertex, CRISPR Therapeutics Get FDA Approval for First CRISPR Gene-Editing Therapy in US (Investopedia) -8.08%
04:37PM	Crispr Stock Whipsaws Lower After FDA Approves Gene-Editing Treatment (Investor's Business Daily)
04:30PM	FDA approves gene-editing therapy for sickle cell disease (Yahoo Finance Video)
02:54PM	FDA Approves First Two Sickle Cell Gene Therapies, bluebird bio Shares Tumble (Barrons.com)
01:45PM	FDA Approves Worlds First Crispr Gene-Editing Drug for Sickle-Cell Disease (The Wall Street Journal)
01:36PM	Loading…
01:36PM	FDA approves first CRISPR gene-editing therapy, Lululemon stock rises: Yahoo Finance Live (Yahoo Finance Video)
01:16PM	Vertex/CRISPR price sickle cell disease gene therapy at $2.2 mln (Reuters)
12:52PM	Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease (Business Wire)
12:46PM	Shares of Crispr Therapeutics Swing After FDA's OK. Is the Stock Safe? (TheStreet.com)
12:00PM	Volatile Crispr Stock Crashes After FDA Approves Gene-Editing Treatment (Investor's Business Daily)
11:02AM	Crispr Stock Rallies Above Buy Point Ahead Of Expected FDA Approval Of Gene-Editing Treatment (Investor's Business Daily)
09:35AM	Crispr Stock Rises Ahead Of Expected FDA Approval Of Gene-Editing Treatment (Investor's Business Daily)
08:15AM	CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried? (Motley Fool)
06:22AM	CRISPR therapy for sickle cell approved by FDA in gene editing milestone (BioPharma Dive)
Dec-07-23 05:30AM	This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics (Motley Fool)
05:21AM	Loading…
05:21AM	5 Unstoppable Trends to Invest $1,000 in for 2024 (Motley Fool)
Dec-06-23 02:00PM	Is This News a Setback or a Step Forward for CRISPR Therapeutics? (Motley Fool)
11:30AM	CRISPR Therapeutics AG (CRSP) Up 20.5% Since Last Earnings Report: Can It Continue? (Zacks)
09:55AM	Wall Street Analysts Think CRISPR Therapeutics AG (CRSP) Could Surge 27.15%: Read This Before Placing a Bet (Zacks)
Dec-05-23 01:15PM	CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline (Zacks)
07:00AM	1 Promising Stock Down 66% That Could Skyrocket in 2024 (Motley Fool)
05:00AM	Better Growth Stock: CRISPR Therapeutics vs. Invitae (Motley Fool)
04:10AM	CRISPR eyes autoimmune disease in revamp of cell therapy plans (BioPharma Dive)
Dec-04-23 08:56PM	The Market's Up This Year. Do You Feel Like You Are Winning? (Motley Fool)
04:15PM	CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease (GlobeNewswire)
08:30AM	You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. (Motley Fool)
05:00AM	If You Invested $5,000 in CRISPR Therapeutics in January, This Is How Much You Would Have Today (Motley Fool)
Dec-02-23 08:30AM	An Important History Lesson for Gene-Editing Investors (Motley Fool)
05:00AM	5 Top Stocks to Buy Before 2024 (Motley Fool)
Dec-01-23 06:15AM	Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? (Motley Fool)
05:15AM	Loading…
05:15AM	Looking for Growth? 2 Top Stocks to Buy Hand Over Fist (Motley Fool)
Nov-29-23 12:00PM	Here's Why CRISPR Therapeutics AG (CRSP) is a Great Momentum Stock to Buy (Zacks)
08:00AM	What's Next For Gene-Editing Darling Crispr After Its 'Historic' First-Ever Approval? (Investor's Business Daily)
Nov-25-23 05:50AM	Investing in These 3 Stocks Now Could Make You a Millionaire Retiree (Motley Fool)
Nov-24-23 11:50AM	CRISPR (CRSP) Rises More Than 40% in Past 3 Months: Here's Why (Zacks)
07:00AM	Gene Editing Will Change Medicineand Maybe Health Investing Too (The Wall Street Journal)
Nov-22-23 01:04PM	CRISPR Therapeutics laid off employees on heels of positive FDA AdComm: sources (FierceBiotech.com)
07:30AM	Is CRISPR Therapeutics the Best Gene-Editing Stock? (Motley Fool)
05:30AM	3 Biotech Stocks That Could Be Millionaire Makers (Motley Fool)
Nov-21-23 08:00AM	These Stocks Are Exploding In The November Stock Market Rally (Investor's Business Daily) -6.39%
Nov-20-23 09:55AM	Wall Street Analysts Believe CRISPR Therapeutics AG (CRSP) Could Rally 33.75%: Here's is How to Trade (Zacks) +6.32%
Nov-19-23 05:30AM	Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire? (Motley Fool)
Nov-18-23 06:49AM	3 Monster Stocks in the Making (Motley Fool)
Nov-17-23 06:45PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research) +14.64%
11:12AM	Why CRISPR Therapeutics Stock Is Jumping Again Today (Motley Fool)
11:01AM	CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News (Investor's Business Daily)
08:15AM	Cutting-Edge Crispr Therapeutics Has Made a Long Base: Time to Get Onboard? (TheStreet.com)
Nov-16-23 04:06PM	Market Today: CRISPR Therapeutics and Vertex Pharmaceuticals Make History with UK Drug Approval (GuruFocus.com) +5.32%
04:03PM	Crispr Surges After Winning The First-Ever Approval For A CRISPR-Based Gene-Editing Drug (Investor's Business Daily)
01:07PM	U.K. Approves First Genetic Scissors Treatment (Barrons.com)
11:47AM	CRISPR (CRSP), Vertex Get UK Nod for First Gene Therapy Casgevy (Zacks)
09:20AM	Morning Brew: Walmart Slips on Forecast, Alibaba (BABA) faced an 8% drop after its ... (GuruFocus.com)
08:46AM	CRISPR Therapeutics (CRSP) Stock Jumps as U.K. Authorizes Gene Therapy (InvestorPlace)
07:15AM	Worlds first CRISPR medicine approved in UK for sickle cell, beta thalassemia (BioPharma Dive)
05:30AM	Can CRISPR Therapeutics Stock Double in 5 Years? Here's What It Would Take. (Motley Fool)
03:17AM	UK authorises gene therapy for blood disorders in world first (Reuters)
01:45AM	Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia (Business Wire)
Nov-14-23 05:00AM	2 Stocks to Buy Hand Over Fist as the S&P 500 Rockets Higher (Motley Fool) +6.33%
Nov-11-23 08:30AM	1 No-Brainer Stock to Buy and Hold for 10 Years (Motley Fool)
Nov-09-23 03:37PM	3 Biotech Stocks That Are Betting on the Future of Gene Editing (InvestorPlace) -6.32%
Nov-08-23 05:24PM	3 Biotech Stocks With the Strongest Clinical Pipelines (InvestorPlace) -6.59%
02:33PM	CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade (Investor's Business Daily)
10:07AM	Why CRISPR Therapeutics Stock Could Be About to Take Off (Motley Fool)
Nov-07-23 06:52PM	Why CRISPR Therapeutics Stock Crushed the Market Today (Motley Fool) +13.57%
01:28PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research)
10:11AM	CRISPR Therapeutics (CRSP) Q3 Loss Narrower Than Expected (Zacks)
09:30AM	CRISPR Therapeutics AG (CRSP) Recently Broke Out Above the 200-Day Moving Average (Zacks)
Nov-06-23 05:30PM	CRISPR Therapeutics AG (CRSP) Reports Q3 2023 Financial Results, Highlights Progress in ... (GuruFocus.com)
04:15PM	CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
05:01AM	CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023 (GlobeNewswire)
Nov-05-23 08:30AM	2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now (Motley Fool)
Nov-03-23 09:56AM	Why CRISPR Therapeutics Stock Charged Northward This Week (Motley Fool) +10.42%
09:30AM	CRISPR Therapeutics AG (CRSP) Recently Broke Out Above the 50-Day Moving Average (Zacks)
08:05AM	Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA (Motley Fool)
05:00AM	3 Healthcare Stocks to Buy Hand Over Fist in November (Motley Fool)
Nov-02-23 09:55AM	Wall Street Analysts See a 108.46% Upside in CRISPR Therapeutics AG (CRSP): Can the Stock Really Move This High? (Zacks) +5.55%
09:35AM	CRISPR Therapeutics AG (CRSP) Crossed Above the 20-Day Moving Average: What That Means for Investors (Zacks)
05:30AM	One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics? (Motley Fool)
02:48AM	CRISPR Therapeutics AG (CRSP) Surges 12.4%: Is This an Indication of Further Gains? (Zacks)
Nov-01-23 04:16PM	Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug (Investor's Business Daily) +12.38%
10:11AM	CRSP Stock Alert: Can CRISPR Therapeutics Short Squeeze Higher? (InvestorPlace)
10:01AM	Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-31-23 06:26PM	FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study (Reuters)
05:53PM	CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease (GlobeNewswire)
05:20PM	15 Best ARK Stocks To Buy Now (Insider Monkey)
05:07PM	Market Today: Stanley Druckenmiller Criticizes Yellen, CRISPR Therapeutics on Hold, and Automakers (GuruFocus.com)
03:43PM	FDA Advisors Review Crispr Gene-Editing Treatment for Sickle Cell Anemia (Barrons.com)
10:01AM	Will CRISPR Therapeutics AG (CRSP) Report Negative Q3 Earnings? What You Should Know (Zacks)
07:05AM	CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD) (GlobeNewswire)
06:50AM	FDA Advisors Consider Crispr Gene-Editing Treatment for Sickle Cell Anemia (Barrons.com)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
08:30AM	Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient (Motley Fool)
Oct-27-23 03:10PM	CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy (InvestorPlace)
12:32PM	CRISPR Therapeutics Is in Search of a Proper Bottom (TheStreet.com)
09:27AM	UPDATE 3-US FDA advisers to determine need for more studies of Vertex/CRISPR gene therapy (Reuters)
Oct-26-23 06:00PM	CRISPR Therapeutics AG (CRSP) Stock Moves -0.18%: What You Should Know (Zacks)
08:22AM	CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards? (Zacks)
05:00AM	2 Fantastic Growth Stocks to Buy Hand Over Fist (Motley Fool)
Oct-25-23 08:45AM	2 Biotech Stocks You Can Buy and Hold for the Next Decade (Motley Fool) -5.61%
Oct-23-23 09:40AM	Intellia (NTLA) Focuses on Developing Gene-Editing Therapies (Zacks)

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kulkarni Samarth	Chief Executive Officer	May 30	Option Exercise	19.12	25,000	478,000	412,377	Jun 01 05:44 PM
Kulkarni Samarth	Chief Executive Officer	May 30	Sale	64.88	25,000	1,621,894	387,377	Jun 01 05:44 PM
Kulkarni Samarth	Chief Executive Officer	Apr 25	Option Exercise	19.12	25,000	478,000	412,377	Apr 27 05:37 PM
Kulkarni Samarth	Chief Executive Officer	Apr 25	Sale	50.67	25,000	1,266,638	387,377	Apr 27 05:37 PM
Kulkarni Samarth	Chief Executive Officer	Mar 29	Option Exercise	19.12	25,000	478,000	412,377	Mar 31 05:49 PM
Kulkarni Samarth	Chief Executive Officer	Mar 29	Sale	44.46	25,000	1,111,504	387,377	Mar 31 05:49 PM
Kulkarni Samarth	Chief Executive Officer	Feb 27	Option Exercise	19.12	25,000	478,000	400,988	Mar 01 06:11 PM
Kulkarni Samarth	Chief Executive Officer	Feb 27	Sale	48.25	25,000	1,206,243	375,988	Mar 01 06:11 PM
Kulkarni Samarth	Chief Executive Officer	Jan 27	Option Exercise	19.12	25,000	478,000	394,111	Jan 31 05:34 PM
Kulkarni Samarth	Chief Executive Officer	Jan 27	Sale	51.47	25,000	1,286,798	369,111	Jan 31 05:34 PM
Kulkarni Samarth	Chief Executive Officer	Dec 28	Option Exercise	19.12	25,000	478,000	394,111	Dec 30 05:33 PM
Kulkarni Samarth	Chief Executive Officer	Dec 28	Sale	40.93	25,000	1,023,290	369,111	Dec 30 05:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRSP

CRISPR Therapeutics AG

Upgrade your FINVIZ experience